GT Biopharma enters Phase 1 clinical trial agreement with U of Minnesota for GTB-3650 in MDS/AML

GT Biopharma, Inc.

Agreement for investigator-initiated Phase 1 trial of GTB-3650 (CD16/IL-15/CD33 TriKE) in high-risk MDS, relapsed/refractory AML, MRD.
Budget up to ~$2 million over three years, funded entirely by GT Biopharma.
University of Minnesota sponsors the IND and acts as sponsor-investigator; Company supplies study drug and funding.
Study data owned by University; Company may use data subject to consent and laws; each party may publish results.
Agreement terminable on 30 days' notice by either party, or immediately for safety reasons.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.